Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Change in Accured Expenses (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Change in Accured Expenses for 9 consecutive years, with $12.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 193.54% year-over-year to $12.9 million, compared with a TTM value of $13.2 million through Dec 2025, up 183.13%, and an annual FY2025 reading of $13.2 million, up 183.13% over the prior year.
  • Change in Accured Expenses was $12.9 million for Q4 2025 at Puma Biotechnology, up from $5.3 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $22.2 million in Q3 2021 and bottomed at -$30.9 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is -$1.9 million, with a median of -$131000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses crashed 4182.08% in 2021, then soared 1283.49% in 2022.
  • Year by year, Change in Accured Expenses stood at $1.5 million in 2021, then skyrocketed by 1283.49% to $20.7 million in 2022, then plummeted by 45.26% to $11.3 million in 2023, then tumbled by 221.48% to -$13.8 million in 2024, then surged by 193.54% to $12.9 million in 2025.
  • Business Quant data shows Change in Accured Expenses for PBYI at $12.9 million in Q4 2025, $5.3 million in Q3 2025, and $4.9 million in Q2 2025.